화합물

본 발명은 EGFR 돌연변이를 함유하는 TMLR, TMLRCS, LR 및 LRCS의 선택성 알로스테릭 억제제 화합물, 이의 제조 방법, 이를 함유하는 약학 조성물, 및 치료 활성 물질로서 이의 용도를 제공한다. The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and thei...

Full description

Saved in:
Bibliographic Details
Main Authors RICCI ANTONIO, NAGEL YVONNE ALICE, KUHN BERND, RUEHER DANIEL, JAESCHKE GEORG, DUPLESSIS MARTIN, STEINER SANDRA
Format Patent
LanguageKorean
Published 12.02.2020
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:본 발명은 EGFR 돌연변이를 함유하는 TMLR, TMLRCS, LR 및 LRCS의 선택성 알로스테릭 억제제 화합물, 이의 제조 방법, 이를 함유하는 약학 조성물, 및 치료 활성 물질로서 이의 용도를 제공한다. The present invention provides substituted isoindole compounds which are selective allosteric EGFR inhibitors, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, generally of Formula:or a pharmaceutically acceptable salt thereof.
Bibliography:Application Number: KR20197038496